Last reviewed · How we verify
PG201 tablet
PG201 tablet is a small molecule that targets the SGLT2 receptor.
PG201 tablet is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | PG201 tablet |
|---|---|
| Also known as | botanical drug |
| Sponsor | PMG Pharm Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, PG201 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of PG201's interaction with SGLT2 are not well-documented.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis (PHASE2)
- Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PG201 tablet CI brief — competitive landscape report
- PG201 tablet updates RSS · CI watch RSS
- PMG Pharm Co., Ltd portfolio CI